HCi VioCare Announces Collaboration Between UK-Based Subsidiary and University of Strathclyde

GLASGOW, SCOTLAND / ACCESSWIRE / October 7, 2014 / HCi VioCare VICA, is pleased to announce that its wholly owned UK subsidiary, HCi VioCare Technologies Limited ("HCi VioCare") has entered into an agreement with the Biomedical Engineering Department of the University of Strathclyde in Glasgow, one of the leading Bioengineering and Prosthetics and Orthotics (P&O) research institutes worldwide, to further the development of its innovative technologies through access to the University's laboratory space and machinery.

HCi VioCare has acquired a pipeline of technologies with the goal of helping revolutionize the prevention and management of the diabetic foot, amputations and complications associated with mobility constraints, thereby improving the quality of life for amputees and the physically impaired alike. The Company's first commercial prototype, a system for monitoring of the diabetic foot condition, is in the final stages of testing and the Company is ready to engage with appropriate licensing partners.

This collaboration with the Biomedical Engineering Department of the University of Strathclyde is founded on strong historical ties, with HCi VioCare Chief Technology officer, Dr Christos Kapatos, who received his PhD at the institution. Further collaboration in the future is envisaged in order to continue to develop breakthroughs in P&O care.

About the Biomedical Engineering Department of the University of Strathclyde

The Biomedical Engineering Department of the University of Strathclyde in Glasgow is an internationally recognized center of excellence for postgraduate education and research at the interface between engineering and the life sciences, with particular emphasis on clinically-related research. Established in 1963, as the first institute of its kind in the UK, the department has been in the forefront of research and innovation ever since.

About HCi Viocare Technologies Ltd

The company is a wholly owned subsidiary of American-based HCi VioCare (OTCQB/OTCBB:VICA), a Company in the process of establishing a chain of P&O and rehabilitation clinics across Europe. The technology subsidiary, HCi Viocare Technologies Ltd. will undertake the R&D and commercialisation of an existing pipeline of innovative technologies in the field of P&O, with the benefit of a deep understanding of its target market to be obtained from operating the clinics which also provide a ready-made distribution channel.

About the marketplace

The field of Bioengineering and Prosthetics and Orthotics is considered by many to be one of the most promising and rapidly growing technological fields that will generate some of the greatest advances in human-integrated-technology which will improve the lives of millions of people, in the next decades (source:http://fastfuture.com/wp-content/uploads/2010/01/FastFuture_Shapeofjobstocome_FullReport1.pdf). The rise of diabetes globally is having a huge impact in the P&O field. It is reported that every 20 seconds an amputation is taking place somewhere in the world due to diabetes (347 million diabetic people worldwide according to WHO), and this figure is expected to rise as more people are diagnosed with the disease (source: http://www.iwgdf.org/ & http://www.who.int/mediacentre/factsheets/fs312/en/ ).

Forward Looking Statement Disclaimer

Safe Harbor: Pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995, and within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Exchange Act of 1934, any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals and assumptions of future events or performance are not statements of historical fact and may be "forward-looking statements." Such statements include but are not limited to: the successful testing of the company's first prototype, the company's ability to engage licensing partners for the prototype, or the company's ability to establish a chain of P&O and rehabilitation clinics across Europe. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this release may be identified through the use of words such as "expects," "will," "anticipates," "estimates," "believes," or statements indicating certain actions such as "may," "could," or "might" occur. Such statements reflect the current views of VICA with respect to future events and are subject to certain assumptions, including those described in this release. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products, services, and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. HCi VioCare does not undertake any responsibility to update the "forward-looking" statements contained in this news release. 

CONTACT:

HCi VioCare

Sotiris Leontaritis, President

For further information please visit our site http://www.viocare.eu/ or contact us at info@viocare.eu 

SOURCE: HCi VioCare